{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:32:50Z","timestamp":1765596770468,"version":"3.48.0"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.6617-25","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:08:11Z","timestamp":1765404491000},"source":"Crossref","is-referenced-by-count":0,"title":["Successes and Challenges of Bispecific T-cell Engager Antibodies in the Treatment of Multiple Myeloma"],"prefix":"10.2169","author":[{"given":"Ichiro","family":"Hanamura","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Aichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivasundaram","family":"Karnan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Aichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Food and Nutritional Environment, College of Human Life and Environment, Kinjo Gakuin University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyoshi","family":"Takami","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Aichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. American Journal of Hematology 99: 3-25, 2024.","DOI":"10.1002\/ajh.27422"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Kumar SK, Dispenzieri A, Lacy MQ. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28: 1122-1128, 2014.","DOI":"10.1038\/leu.2013.313"},{"key":"3","unstructured":"3. Mateos MV, San-Miguel J. Management of multiple myeloma in the newly diagnosed patient. Hematology American Society of Hematology Education Program 2022: 170-178, 2022."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gandhi UH, Cornell RF, Lakshman A. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33: 2266-2275, 2019.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36: 1371-1376, 2022.","DOI":"10.1038\/s41375-022-01531-2"},{"key":"6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-022-00709-2","volume":"12","author":"LJ Costa","year":"2022","unstructured":"6. Costa LJ, Wong SW, Bermudez A. Overview of bispecific antibodies in multiple myeloma. Blood Cancer Journal 12: 120-120, 2022.","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Moreau P. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 387: 2431-2444, 2022.","DOI":"10.1056\/NEJMc2211969"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29: 2259-2267, 2023.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 387: 2232-2244, 2022.","DOI":"10.1056\/NEJMoa2204591"},{"key":"10","first-page":"245","volume":"8","author":"NJ Bahlis","year":"2024","unstructured":"10. Bahlis NJ, Baz R, Harrison SJ. Clinical activity of bispecific antibodies in primary plasma cell leukemia. Blood Advances 8: 245-257, 2024.","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"key":"11","unstructured":"11. Cohen AD, Costa LJ, Krishnan AY. Teclistamab treatment of patients with relapsed\/refractory multiple myeloma after BCMA-directed CAR T-cell therapy. Blood 143: 1650-1661, 2024."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. van de Donk NWCJ, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. The Lancet Haematology 11: e693-e707, 2024.","DOI":"10.1016\/S2352-3026(24)00186-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 7: 1187-1199, 2015.","DOI":"10.2217\/imt.15.77"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Carpenter RO, Evbuomwan MO, Pittaluga S. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 19: 2048-2060, 2013.","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pont MJ, Hill T, Cole GO. \u03b3-Secretase inhibition increases surface expression of BCMA and enhances efficacy of BCMA-targeted T-cell therapies. Blood 134: 1585-1597, 2019.","DOI":"10.1182\/blood.2019000050"},{"key":"16","unstructured":"16. Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma. J Clin Oncol 42: 2702-2712, 2024."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Kiesel B, Osawa M, Masilamani M, et al. Informing the Recommended Phase III Dose of Alnuctamab, a CD3\u00d7 BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis. Clinical pharmacology and therapeutics 116: 866-874, 2024.","DOI":"10.1002\/cpt.3353"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. D'Souza A, Shah N, Rodriguez C, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma. J Clin Oncol 40: 3576-3586, 2022.","DOI":"10.1200\/JCO.22.01504"},{"key":"19","unstructured":"19. Gagelmann N, Khandelwal H, Iacobelli S. Bispecific antibody therapy in plasma cell leukemia: a multicenter analysis. Leukemia 38: 556-564, 2024."},{"key":"20","unstructured":"20. Krishnan AY, Cohen AD, Usmani SZ. BCMA bispecific antibody therapy after BCMA CAR T-cell relapse. Blood Adv 8: 1225-1235, 2024."},{"key":"21","unstructured":"21. Buelow B, Costa LJ, Lee HC. GPRC5D: A novel target in multiple myeloma. Clin Cancer Res 29: 673-682, 2023."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol 12: e269-e281, 2025.","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood 143: 1211-1217, 2024.","DOI":"10.1182\/blood.2023022499"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cohen YC. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma (RedirecTT-1). N Engl J Med 392: 138-149, 2025.","DOI":"10.1056\/NEJMoa2406536"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tan CR, Asoori S, Huang CY, et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J 15: 53, 2025.","DOI":"10.1038\/s41408-025-01259-z"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Richter J, Thomas SK, Krishnan AY, et al. Cevostamab in Patients with Heavily Pretreated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies. Blood 144 (Supplement 1): 1021-1021, 2024.","DOI":"10.1182\/blood-2024-199542"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Pan D, Richter J. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma. Current Hematologic Malignancy Reports 19: 237-245, 2024.","DOI":"10.1007\/s11899-024-00740-z"},{"key":"28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-024-01114-7","volume":"14","author":"R Chakraborty","year":"2024","unstructured":"28. Chakraborty R, Cheruvalath H, Patwari A, et al. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma. Blood Cancer Journal 14: 137, 2024.","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lesokhin AM, Richter J, Trudel S, et al. Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study. Blood 140 (Supplement 1): 4415-4417, 2022.","DOI":"10.1182\/blood-2022-157547"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Razzo B, Grady C, Susanibar-Adaniya S, et al. A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec). Blood 142 (Supplement 1): 3394-3394, 2023.","DOI":"10.1182\/blood-2023-177735"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Mor\u00e8 S, Corvatta L, Manieri VM, Morsia E, Poloni A, Offidani M. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment. Pharmaceuticals (Basel, Switzerland) 16: 2023.","DOI":"10.3390\/ph16111628"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. van de Donk NWCJ, Vega G, Perrot A, et al. First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results. Journal of Clinical Oncology 43 (16_suppl): 7505-7505, 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.7505"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. Journal of Hematology & Oncology 16: 92, 2023.","DOI":"10.1186\/s13045-023-01489-3"},{"key":"#cr-split#-34.1","unstructured":"34. Lichtman EI, Khot A, Augustson B, et al. Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed\/refractory multiple myeloma (RRMM)-Dose escalation"},{"key":"#cr-split#-34.2","doi-asserted-by":"crossref","unstructured":"(DE) results. Journal of Clinical Oncology 43 (16_suppl): 7514-7514, 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.7514"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6617-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:29:01Z","timestamp":1765596541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6617-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6617-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"6617-25"}}